Impact of the modulator elexacaftor/tezacaftor/ivacaftor (ETI) on the complexity of prescriptions and the clinical stage of children and adolescents with cystic fibrosis. (2026). Research, Society and Development, 15(1), e7715150550. https://doi.org/10.33448/rsd-v15i1.50550